Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sergei Biryukov"'
Autor:
Sergei Biryukov, Jennifer L. Dankmeyer, Zain Shamsuddin, Ivan Velez, Nathaniel O. Rill, Raysa Rosario-Acevedo, Christopher P. Klimko, Jennifer L. Shoe, Melissa Hunter, Michael D. Ward, Lisa H. Cazares, David P. Fetterer, Joel A. Bozue, Patricia L. Worsham, Christopher K. Cote, Kei Amemiya
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
Relatively recent advances in plague vaccinology have produced the recombinant fusion protein F1-V plague vaccine. This vaccine has been shown to readily protect mice from both bubonic and pneumonic plague. The protection afforded by this vaccine is
Externí odkaz:
https://doaj.org/article/d765265a385a47d2be35ccc40370ffa6
Publikováno v:
PLoS ONE, Vol 15, Iss 8, p e0237786 (2020)
Plasmodium falciparum malaria killed 451,000 people in 2017. Merozoites, the stage of the parasite that invades RBCs, are a logical target for vaccine development. Treatment with the protease inhibitor E64 followed by filtration through a 1.2 μm fil
Externí odkaz:
https://doaj.org/article/f086876297a248239b25ead2c325c4c5
Autor:
Sergei Biryukov, Evelina Angov, Mary E. Landmesser, Michele D. Spring, Christian F. Ockenhouse, José A. Stoute
Publikováno v:
EBioMedicine, Vol 9, Iss C, Pp 207-216 (2016)
Plasmodium falciparum malaria is a deadly pathogen. The invasion of red blood cells (RBCs) by merozoites is a target for vaccine development. Although anti-merozoite antibodies can block invasion in vitro, there is no efficacy in vivo. To explain thi
Externí odkaz:
https://doaj.org/article/f691a1150b7545f18a3283e024e04856
Autor:
Kristen D. Yetming, Lena N Lupey-Green, David J. Hughes, JJ L. Miranda, Sergei Biryukov, Jeffery T. Sample, Elessa M. Marendy
Publikováno v:
J Virol
Funding: U.S. Public Health Service grant AI110328 to J.T.S. and in part by Commonwealth Universal Research Enhancement (CURE) funds. L.N.L. received support from National Cancer Institute training grant T32 CA060395, and is a Lymphoma Research Found
Autor:
José A. Stoute, Sergei Biryukov
Publikováno v:
Complement Activation in Malaria Immunity and Pathogenesis ISBN: 9783319772578
The complement system consists of a complex cascade of zymogens that leads to the formation of opsonins (predominantly C3b and C4b) that promote phagocytosis and the insertion of the membrane attack complex into the membranes, resulting in lysis. It
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::032ca00e55700d2cb9d6b3e8e3613daf
https://doi.org/10.1007/978-3-319-77258-5_1
https://doi.org/10.1007/978-3-319-77258-5_1
Autor:
José A. Stoute, Sergei Biryukov
Publikováno v:
Trends in Molecular Medicine. 20:293-301
Complement is activated during malaria infection, but there is little evidence that it benefits the host. On the contrary, growing evidence points to the central role of complement activation in the pathogenesis of complicated malaria. Recent evidenc
Autor:
José A. Stoute, Sergei Biryukov
Publikováno v:
EBioMedicine
Autor:
Ajjampura C. Vinayaka, Sergei Biryukov, Kanchugarakoppal S. Rangappa, D. Channe Gowda, José A. Stoute, M. P. Sadashiva, Xianzhu Wu
Publikováno v:
Organicbiomolecular chemistry. 12(42)
A new strategy was developed to synthesize 1,2-disubstituted 4-quinolones in good yield starting from 1,3-bisaryl-monothio-1,3-diketone substrates. The synthesized compounds were evaluated for antimalarial activity using Plasmodium falciparum strains
Autor:
Sergei Biryukov, José Stoute
Publikováno v:
The Journal of Immunology. 192:67.5-67.5
Malaria is an infectious disease caused by an intracellular protist of the genus Plasmodium that invades red blood cells (RBCs). Experimental vaccines that target the blood stage of the parasite (merozoites) induce a potent humoral immune response bu
Autor:
Mary E. Landmesser, Sergei Biryukov, José A. Stoute, Evelina Angov, Christian F. Ockenhouse, Michele D. Spring
Publikováno v:
EBioMedicine, Vol 9, Iss C, Pp 207-216 (2016)
EBioMedicine
EBioMedicine
Plasmodium falciparum malaria is a deadly pathogen. The invasion of red blood cells (RBCs) by merozoites is a target for vaccine development. Although anti-merozoite antibodies can block invasion in vitro, there is no efficacy in vivo. To explain thi